Emirates Oncology Society – EOS shared a post on LinkedIn:
“Rethink 1L HR+/HER2−
EPISODE 1 | Rethinking Progression
Our experts explore a major shift in HR+ metastatic breast cancer — from waiting for radiological progression to earlier, molecularly guided treatment.
With ESR1 blood testing and targeted oral therapies, evidence such as SERENA-6 is reshaping treatment sequencing and patient care.
Featuring: Dr. Hassan Jaafar, Dr. Saeed Rafii, Dr. Dina Hamza, and Dr. Husam Marashi
Endorsed by EOS | Supported by AstraZeneca | Managed by Conveners
Watch Episode 1 and discover how molecular progression may matter before radiological progression becomes visible.”
Proceed to the video attached to the post.
Other posts about Emirates Oncology Society on OncoDaily.